Figures & data
Figure 1 Change from baseline in HbA1c over 24 weeks in the full analysis set.
Notes: Reprinted from the Lancet, 382(9902), Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ, Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial, 1413–1423, Copyright 2013, with permission from Elsevier.Citation24 Adjusted mean change in HbA1c. The error bars represent SE. The full analysis set consisted of all randomized patients who received at least one dose of study drug and who had a baseline and at least one on-treatment HbA1c measurement. Data are from a mixed model for repeated measurements, using observed cases with treatment, visit, previous use of insulin, and visit by treatment interactions as fixed classification effects and baseline HbA1c as a linear covariate.
Abbreviations: HbA1c, hemoglobin A1c; SE, standard error of the mean.
Abbreviations: HbA1c, hemoglobin A1c; SE, standard error of the mean.
Figure 2 Hypoglycemia in the treated set of patients.
Notes: Reprinted from the Lancet, 382(9902), Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ, Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial, 1413–1423, Copyright 2013, with permission from Elsevier.Citation24 The treated set consisted of all patients who received at least one dose of study drug. *Confirmed plasma glucose concentration of 3.9 mmol/L or less, or symptoms attributed to hypoglycemia, or both.
Abbreviations: INS, insulin (with or without metformin); MET, metformin only; SU, sulfonylurea (with or without other antidiabetic drugs).
Abbreviations: INS, insulin (with or without metformin); MET, metformin only; SU, sulfonylurea (with or without other antidiabetic drugs).
